Skip to main content
SpringerLink
Log in

Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature

  • REVIEW
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

A role for CD20 antibodies in treating prostate cancer has not yet been established. We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Oster MW, Wolff M, Starrett S (1979) Prostate cancer mimicking malignant lymphoma. Med Pediatr Oncol 7:387–392

    Article  CAS  PubMed  Google Scholar 

  2. Stein BS, Shea FJ (1983) Metastatic carcinoma of the prostate presenting radiographically as lymphoma. J Urol 130:362–364

    CAS  PubMed  Google Scholar 

  3. Liel Y, Biderman A, Biran C et al (1987) Carcinoma of the prostate clinically and radiologically simulating malignant lymphoma. J Surg Oncol 35:113–116

    Article  CAS  PubMed  Google Scholar 

  4. Phillips SM, Ferry DR, Lee SJ (1994) Carcinoma of the prostate mimicking lymphoma. Br J Urol 73:590–591

    Article  CAS  PubMed  Google Scholar 

  5. Ahn MJ, Oh SJ, Lee YY et al (1997) A case of prostate cancer in 34 year old man presenting with generalized lymphadenopathy mimicking malignant lymphoma. J Korean Med Sci 12:262–265

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Oyan B, Engin H, Yalcin S (2002) Generalized lymphadenopathy: a rare presentation of disseminated prostate cancer. Med Oncol Northwood Lond Engl 19:177–179. doi:10.1385/MO:19:3:177

    Article  Google Scholar 

  7. Biyani CS, Basu S, Bottomley DM, Shah TK (2003) Prostatic adenocarcinoma masquerading as lymphoma and presentation with axillary-subclavian vein thrombosis. Urol Oncol 21:3–6

    Article  PubMed  Google Scholar 

  8. Heresi GA, Wang J, Taichman R et al (2005) Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol 23:261–267. doi:10.1016/j.urolonc.2005.02.004

    Article  CAS  PubMed  Google Scholar 

  9. Moura FM, Garcia LT, Castro LPF, Ferrari TCA (2006) Prostate adenocarcinoma manifesting as generalized lymphadenopathy. Urol Oncol 24:216–219. doi:10.1016/j.urolonc.2005.06.022

    Article  PubMed  Google Scholar 

  10. Saad S, Hayek T, Vlodavsky E, et al. Generalized lymphadenopathy as the first manifestation of prostatic cancer. Gd Rounds 10:67–70.

  11. Benderli-Cihan Y, Deniz K, Sofikerim M (2011) A Case of Prostate Adenocarcinoma In A 67-Year-Old Man Manifesting As Generalized Lymphaenopathy Mimicking Lymphoma. Kulak Burun Boğaz Ihtis Derg KBB J Ear Nose Throat 14:381–385

    Google Scholar 

  12. Cetin B, Cetin Z, Buyukberber S et al (2011) Generalized lymphadenopathy: unusual presentation of prostate adenocarcinoma. Case Rep Urol 2011:439732. doi:10.1155/2011/439732

    PubMed Central  PubMed  Google Scholar 

  13. Krpina K, Oguic R, Pavlovic I et al (2011) Prostate cancer manifesting as generalized lymphadenopathy. Rev Rom Urol 10:72–74

    Google Scholar 

  14. Andre F, Cabioglu N, Assi H et al (2006) Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO 17:945–951. doi:10.1093/annonc/mdl053

    Article  CAS  Google Scholar 

  15. Kakinuma T, Hwang ST (2006) Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79:639–651. doi:10.1189/jlb.1105633

    Article  CAS  PubMed  Google Scholar 

  16. Zlotnik A, Burkhardt AM, Homey B (2011) Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11:597–606. doi:10.1038/nri3049

    Article  CAS  PubMed  Google Scholar 

  17. Gladson CL, Welch DR (2008) New insights into the role of CXCR4 in prostate cancer metastasis. Cancer Biol Ther 7:1849–1851

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Taichman RS, Cooper C, Keller ET et al (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832–1837

    CAS  PubMed  Google Scholar 

  19. López-Giral S, Quintana NE, Cabrerizo M et al (2004) Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 76:462–471. doi:10.1189/jlb.1203652

    Article  PubMed  Google Scholar 

  20. Alfonso-Pérez M, López-Giral S, Quintana NE et al (2006) Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol 79:1157–1165. doi:10.1189/jlb.1105623

    Article  PubMed  Google Scholar 

  21. O’Hayre M, Salanga CL, Kipps TJ et al (2010) Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PloS One 5:e11716. doi:10.1371/journal.pone.0011716

    Article  PubMed Central  PubMed  Google Scholar 

  22. Yang J, Wang S, Zhao G, Sun B (2011) Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. J Exp Clin Cancer Res CR 30:51. doi:10.1186/1756-9966-30-51

    Article  PubMed  Google Scholar 

  23. Buonamici S, Trimarchi T, Ruocco MG et al (2009) CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459:1000–1004. doi:10.1038/nature08020

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Ammirante M, Luo J-L, Grivennikov S et al (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464:302–305. doi:10.1038/nature08782

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Oosterheert JJ, Budel LM, Vos P, Wittebol S (2007) High levels of serum prostate-specific antigen due to PSA producing follicular non-Hodgkin’s lymphoma. Eur J Haematol 79:155–158. doi:10.1111/j.1600-0609.2007.00883.x

    Article  CAS  PubMed  Google Scholar 

  26. Djavan B, Keffer JH, Molberg K, Roehrborn CG (1995) False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney. Urology 45:875–878. doi:10.1016/S0090-4295(99)80099-5

    Article  CAS  PubMed  Google Scholar 

  27. Nadler RB, Humphrey PA, Smith DS et al (1995) Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154:407–413

    Article  CAS  PubMed  Google Scholar 

  28. Wiernik PH (2008) Serum CA125 and PSA concentrations in patients with lymphoma. Clin Adv Hematol Oncol HO 6:527–531

    Google Scholar 

  29. Terris MK, Hausdorff J, Freiha FS (1997) Hematolymphoid malignancies diagnosed at the time of radical prostatectomy. J Urol 158:1457–1459

    Article  CAS  PubMed  Google Scholar 

  30. Sella A, Konichezky M, Flex D et al (2000) Low PSA metastatic androgen-independent prostate cancer. Eur Urol 38:250–254

    Article  CAS  PubMed  Google Scholar 

  31. Tu S-M, Reyes AO, Fanning T et al (2002) Advanced prostate carcinoma and elevated serum CA-125 level 31. J Clin Oncol Off J Am Soc Clin Oncol 21:2445

    Google Scholar 

  32. Cancer Genetics. http://www.cancerindex.org/geneweb/clinkc17.htm (Accessed, September, 2013).

  33. Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol Off J Am Soc Clin Oncol 22:735–742. doi:10.1200/JCO.2004.05.055

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We gratefully acknowledge Dr. Alastair Deery for the pathology processing that contributed to the development of the article.

Competing interests

Moshe Rogosnitzky has a pending patent for the use of CD20 antibodies in treating prostate cancer

Author information

Authors and Affiliations

  1. Division of Clinical Sciences, St George’s University of London, Cranmer Terrace, London, SW17 0RE, UK

    Angus Dalgleish

  2. Medical Assessment Unit, Queen Alexandra Hospital, Portsmouth, PO6 3LY, UK

    Peter Featherstone

  3. MedInsight Research Institute, Island West, Steep, GU32 1AE, UK

    Viatcheslav Vlassov

  4. MedInsight Research Institute, Yitzchak 37, Telz Stone, 9083800, Israel

    Moshe Rogosnitzky

Authors
  1. Angus Dalgleish
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Featherstone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Viatcheslav Vlassov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Moshe Rogosnitzky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Moshe Rogosnitzky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dalgleish, A., Featherstone, P., Vlassov, V. et al. Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature. Invest New Drugs 32, 1048–1052 (2014). https://doi.org/10.1007/s10637-014-0063-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-014-0063-z

Keywords

Search

Navigation